Comparing Weekly GLP-1 Receptor Agonists: Semaglutide 2.0mg Leads in Blood Sugar Control | Research

The takeaway

A network meta-analysis of 12 studies and 6,213 patients found semaglutide 2.0mg weekly was the most effective GLP-1 receptor agonist for lowering HbA1c in type 2 diabetes, with a comparable safety profile to other options.

6,213 patients
Pooled from 12 randomized controlled trials comparing 10 different weekly GLP-1 receptor agonist regimens, with semaglutide 2.0mg ranking first for HbA1c reduction

What the researchers found

The network meta-analysis of 12 RCTs covering 6,213 patients and 10 GLP-1RA regimens produced a clear efficacy ranking for HbA1c reduction: Semaglutide 2.0mg > Semaglutide 1.0mg > Dulaglutide 4.5mg > Semaglutide 0.5mg > Dulaglutide 3.0mg > PEX168 200μg > Dulaglutide 1.5mg > PEX168 100μg > Dulaglutide 0.75mg. All once-weekly GLP-1RAs were significantly better than placebo.

Safety analysis showed comparable hypoglycemia risk across all regimens, and all long-acting GLP-1RAs (except PEX168) had lower rates of diarrhea, nausea, and vomiting than placebo.

Why it matters

With multiple GLP-1 receptor agonist peptide drugs available, clinicians need evidence to guide treatment selection. This analysis provides a direct comparison of options that have rarely been tested head-to-head, helping physicians choose the most effective regimen for their patients while understanding the safety trade-offs.

How the study worked

Systematic review and network meta-analysis of randomized controlled trials from PubMed, EMBASE, and Cochrane Library (searched through June 2022). Included RCTs enrolled type 2 diabetes patients with at least 12 weeks follow-up comparing four weekly GLP-1RAs against each other or placebo. Frequentist random-effect network meta-analysis was used. Registered on PROSPERO (CRD42022342241).

What this study cannot tell us

The minimum 12-week follow-up may miss longer-term efficacy differences and rare adverse events. The analysis focused on glycemic outcomes and did not compare weight loss, cardiovascular outcomes, or kidney effects. Some comparisons in the network may have been informed by few studies. Exenatide once-weekly was not included in the final ranking despite being listed. PEX168 (loxenatide) is primarily available in China, limiting generalizability.

How to read the evidence

Network meta-analysis of randomized controlled trials represents a high level of evidence for comparative effectiveness. The methodology is rigorous (registered protocol, multiple databases, random-effect models), though some network comparisons may be based on indirect evidence rather than head-to-head trials.

When this study was published

Published in 2023 with literature searched through June 2022. Note that tirzepatide (approved 2022) and oral semaglutide were not included, so the landscape has evolved since this analysis.

The bigger picture

This meta-analysis contributes to the evidence base supporting semaglutide as the leading GLP-1 receptor agonist for glycemic control. As these peptide drugs increasingly expand from diabetes into obesity, cardiovascular, kidney, and liver disease, understanding their comparative efficacy helps establish a hierarchy that informs both current prescribing and future drug development.

Questions still open

Does semaglutide's superiority in HbA1c reduction also translate to better cardiovascular and renal outcomes compared to other GLP-1RAs?
How does tirzepatide (dual GIP/GLP-1 agonist) compare to semaglutide 2.0mg in this type of network analysis?
Are the gastrointestinal side effect differences between GLP-1RAs clinically meaningful for patient adherence and quality of life?

Common questions

Which GLP-1 receptor agonist works best for blood sugar control?

According to this analysis, semaglutide 2.0mg weekly was the most effective for lowering HbA1c (a measure of long-term blood sugar control), followed by semaglutide 1.0mg and dulaglutide 4.5mg. However, the best choice for an individual patient also depends on factors like side effects, cost, availability, and other health conditions.

Are GLP-1 receptor agonists safe? What about side effects?

This analysis found that all the weekly GLP-1 receptor agonists had similar and low rates of hypoglycemia (dangerously low blood sugar). Interestingly, most long-acting GLP-1RAs actually had lower rates of nausea, vomiting, and diarrhea than placebo, suggesting these side effects may be less common than often assumed.

Read the original research

Comparative efficacy and safety of glucagon-like peptide 1 receptor agonists for the treatment of type 2 diabetes: A network meta-analysis.

Medicine, 102(27), e34122

View on PubMed ↗Publisher’s paper ↗

Citation

Chen, Han; Li, Xin-Zhu; Chen, Jia-Qing; Ren, Tian-Shu; Zhang, Ying-Shi; Wang, Yi-Nuo; Zhao, Qing-Chun. (2023). Comparative efficacy and safety of glucagon-like peptide 1 receptor agonists for the treatment of type 2 diabetes: A network meta-analysis.. Medicine, 102(27), e34122. https://doi.org/10.1097/MD.0000000000034122